NEO will always be a longer first dose process. Amgen will want to start them on HOT immediately and then transition to NEO when it is ready. Also, the overall treatment cost of HOT will be much lower than NEO, which will be an appeal to some markets.
Dramatic,overstating? I was just stating what I think,did`nt realize it came across as drama. Sorry if my optimistic opinion offends you,but I believe what I believe,which is that Amgn could jump soon,instead of dealing with Competition and another potential suitor that could end up wanting to buyout Adxs.
News 
Market Data 
Discover 
